A Phase 1 interventional study of MT-1186 and MCI-186 in Healthy Adult Subjects, sponsored by Shionogi. Completed at 1 site in Japan. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Shionogi · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the single-dose bioequivalence of oral suspension and intravenous (IV) formulation of edaravone in the fasting state in healthy adult subjects
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria: Additional screening criteria check may apply for qualification:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy subjects were administered a single dose of Edaravone oral suspension
Drug: MT-1186
Healthy subjects were administered a single dose of Edaravone intravenous formulation
Drug: MCI-186
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone After Oral and Intravenous Administration
Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to Infinity With Extrapolation of the Terminal Phase (AUC0-inf) of Unchanged Edaravone After Oral and Intravenous Administration
Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Maximum Plasma Concentration (Cmax) of Unchanged Edaravone After Oral and Intravenous Administration
Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Time to Reach Maximum Plasma Concentration (Tmax)
Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to 24 Hours (AUC0-24)
Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; Day 2 at 24 hrs ; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75,2, 3, 4, 6, 8, 12 hrs; Day 2 at 24 hrs.
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Sampling Time-point (for All Time-points) (AUC0-all)
Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Terminal Elimination Half-life (t1/2)
Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Elimination Rate Constant From the Central Compartment (Kel)
Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Mean Residence Time From Time Zero up to Infinity With Extrapolation of the Terminal Phase (MRT0-inf) of Unchanged Edaravone
Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Total Clearance (CL) of Unchanged Edaravone After Intravenous Administration
Time frame: The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Volume of Distribution During Terminal Phase (Vz) of Unchanged Edaravone After Intravenous Administration
Time frame: The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Volume of Distribution at Steady State (Vss) of Unchanged Edaravone After Intravenous Administration
Time frame: The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Apparent Total Clearance (CL/F) of Unchanged Edaravone After Oral Administration
Time frame: The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Apparent Volume of Distribution During Terminal Phase (Vz/F) of Unchanged Edaravone After Oral Administration
Time frame: The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Apparent Volume of Distribution at Steady State (Vss/F) of Unchanged Edaravone After Oral Administration
Time frame: The date of dosing is defined as Day 1. Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Cumulative Amount of Drug Excreted in Urine From Time Zero up to 48 Hours (Ae0-48)
Time frame: Urine samples are collected: Day1 to 6.
Cumulative Percentage of Drug Excreted in Urine From Time Zero up to 48 Hours (Ae0-48)
Time frame: Urine samples are collected: Day1 to 6.
Renal Clearance (CLr) of Unchanged Edaravone
Time frame: Urine samples are collected: Day1 to 6.
Bioavailability (F) of Unchanged Edaravone After Oral Administration
Bioavailability was calculated from ratio of AUC0-inf of unchanged edaravone after oral and intravenous administration.
Time frame: PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 12 hrs; Day 2 at 24 and 36 hrs; Day 3 at 48 hrs. IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75,2, 3, 4, 6, 8, 12 hrs; Day 2 at 24 and 36 hrs; Day 3 at 48hrs.
AUC0-t of Sulfate and Glucuronide Conjugates After Oral and Intravenous Administration
Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
AUC0-inf of Sulfate and Glucuronide Conjugates After Oral and Intravenous Administration
Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Cmax of Sulfate and Glucuronide Conjugates After Oral and Intravenous Administration
Time frame: The date of dosing is defined as Day 1. PO: Day 1 at pre-dose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hrs; IV: Day 1 at pre-dose, 0.25, 0.5, 1, 1.083, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12 hrs; Both groups: Day 2 at 24, 36 hrs; Day 3 at 48 hrs.
Number of Participants With Adverse Events and Adverse Drug Reactions
Time frame: Day 1 to 11
| Milestone | Edaravone Oral Suspensione First, Then Edaravone IV Formulation | Edaravone IV Formulation First, Then Edaravone Oral Suspension |
|---|---|---|
| Started | 21 | 21 |
| Completed | 21 | 21 |
| Not completed | 0 | 0 |
| Milestone | Edaravone Oral Suspensione First, Then Edaravone IV Formulation | Edaravone IV Formulation First, Then Edaravone Oral Suspension |
|---|---|---|
| Started | 21 | 21 |
| Completed | 21 | 21 |
| Not completed | 0 | 0 |
| ng·h/mL | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone After Oral and Intravenous Administration | 1743 ± 534 | 1720 ± 326 |
| ng·h/mL | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time Zero up to Infinity With Extrapolation of the Terminal Phase (AUC0-inf) of Unchanged Edaravone After Oral and Intravenous Administration | 1762 ± 540 | 1736 ± 331 |
| ng/mL | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Unchanged Edaravone After Oral and Intravenous Administration | 1656 ± 733.6 | 1253 ± 228.9 |
| h | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Unchanged edaravone | 0.50 (0.25 to 0.75) | 1.00 (0.98 to 1.02) |
| Sulfate conjugate | 0.75 (0.50 to 1.00) | 1.08 (0.98 to 1.25) |
| Glucuronide Conjugate | 0.75 (0.25 to 1.00) | 1.08 (1.00 to 1.27) |
| ng·h/mL | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Unchanged edaravone | 1735 ± 523 | 1714 ± 317 |
| Sulfate conjugate | 19837 ± 5185 | 14830 ± 3519 |
| Glucuronide Conjugate | 3917 ± 727 | 2288 ± 479 |
| ng·h/mL | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Unchanged edaravone | 1752 ± 532 | 1727 ± 323 |
| Sulfate conjugate | 20035 ± 5252 | 15025 ± 3575 |
| Glucuronide Conjugate | 3927 ± 730 | 2297 ± 481 |
| h | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Unchanged edaravone | 9.75 ± 8.47 | 8.82 ± 8.33 |
| Sulfate conjugate | 5.77 ± 1.85 | 7.58 ± 2.39 |
| Glucuronide Conjugate | 3.75 ± 0.55 | 3.69 ± 0.48 |
| 1/h | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Unchanged edaravone | 0.1194 ± 0.0876 | 0.1156 ± 0.0563 |
| Sulfate conjugate | 0.1295 ± 0.0318 | 0.1010 ± 0.0324 |
| Glucuronide Conjugate | 0.1909 ± 0.0417 | 0.1924 ± 0.038 |
| h | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Mean Residence Time From Time Zero up to Infinity With Extrapolation of the Terminal Phase (MRT0-inf) of Unchanged Edaravone | 2.495 ± 0.903 | 2.333 ± 0.826 |
| L/h | Edaravone IV Formulation |
|---|---|
| Total Clearance (CL) of Unchanged Edaravone After Intravenous Administration | 35.9 ± 7.5 |
| L | Edaravone IV Formulation |
|---|---|
| Volume of Distribution During Terminal Phase (Vz) of Unchanged Edaravone After Intravenous Administration | 418 ± 321 |
| L | Edaravone IV Formulation |
|---|---|
| Volume of Distribution at Steady State (Vss) of Unchanged Edaravone After Intravenous Administration | 63.1 ± 22.0 |
| L/h | Edaravone IV Formulation |
|---|---|
| Apparent Total Clearance (CL/F) of Unchanged Edaravone After Oral Administration | 67.9 ± 30.1 |
| L | Edaravone Oral Suspension |
|---|---|
| Apparent Volume of Distribution During Terminal Phase (Vz/F) of Unchanged Edaravone After Oral Administration | 826 ± 618 |
| L | Edaravone Oral Suspension |
|---|---|
| Apparent Volume of Distribution at Steady State (Vss/F) of Unchanged Edaravone After Oral Administration | 164.0 ± 78.9 |
| mg | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Unchanged edaravone | 0.66 ± 0.21 | 0.52 ± 0.15 |
| Sulfate conjugate | 10.04 ± 8.67 | 7.06 ± 6.43 |
| Glucuronide Conjugate | 125.9 ± 19.0 | 94.3 ± 13.7 |
| percentage of dose | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Unchanged edaravone | 0.629 ± 0.199 | 0.869 ± 0.252 |
| Sulfate conjugate | 6.58 ± 5.68 | 8.09 ± 7.37 |
| Glucuronide Conjugate | 59.8 ± 9.0 | 78.4 ± 11.4 |
| L/h | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Renal Clearance (CLr) of Unchanged Edaravone | 0.424 ± 0.227 | 0.311 ± 0.114 |
Bioavailability was calculated from ratio of AUC0-inf of unchanged edaravone after oral and intravenous administration.
| percentage bioavailability | Edaravone Oral Suspension |
|---|---|
| Bioavailability (F) of Unchanged Edaravone After Oral Administration | 57.3 ± 12.6 |
| ng·h/mL | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Sulfate conjugate | 20031 ± 5255 | 15024 ± 3576 |
| Glucuronide Conjugate | 3914 ± 730 | 2285 ± 481 |
| ng·h/mL | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Sulfate conjugate | 20055 ± 5256 | 15055 ± 3579 |
| Glucuronide conjugate | 3924 ± 731 | 2295 ± 482 |
| ng/mL | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Sulfate conjugate | 7291 ± 1898 | 4843 ± 817.8 |
| Glucuronide conjugate | 2237 ± 388 | 1012 ± 235.7 |
| Participants | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| Number of Participants with Adverse events | 1 | 1 |
| Number of Participants with adverse drug reactions | 0 | 0 |
Collected over Day 1 to Day 11. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Edaravone Oral Suspension | 0/42 (0%) | 0/42 (0%) | 1/42 (2.4%) |
| Edaravone IV Formulation | 0/42 (0%) | 0/42 (0%) | 1/42 (2.4%) |
| Event | Edaravone Oral Suspension | Edaravone IV Formulation |
|---|---|---|
| ConstipationGastrointestinal disorders | 1/42 | 0/42 |
| Aspartate aminotransferase increasedInvestigations | 0/42 | 1/42 |
| Age, Categorical(Participants) | Edaravone Oral Suspensione First, Then Edaravone IV Formulation | Edaravone IV Formulation First, Then Edaravone Oral Suspension | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 21 | 21 | 42 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Edaravone Oral Suspensione First, Then Edaravone IV Formulation | Edaravone IV Formulation First, Then Edaravone Oral Suspension | Total |
|---|---|---|---|
| Female | 7 | 7 | 14 |
| Male | 14 | 14 | 28 |
| Race (NIH/OMB)(Participants) | Edaravone Oral Suspensione First, Then Edaravone IV Formulation | Edaravone IV Formulation First, Then Edaravone Oral Suspension | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 21 | 21 | 42 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Apr 2019, 0 months.
Results were first posted in Jan 2024, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Edaravone